{"id":"f5773e49f229","type":"article","url":"https://hartvaat.nl/2026/08/21/lvad-implantatie-voor-destination-therapy-toont-vergelijkbare-uitkomsten-als-bru/","title":"LVAD-implantatie voor destination therapy toont vergelijkbare uitkomsten als brug naar transplantatie","title_en":"Clinical differences between destination therapy and bridge-to-transplant left ventricular assist device implantation: a 17-year single-center experience in Japan.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs","doi":"10.1007/s10047-026-01581-8","source_url":"https://doi.org/10.1007/s10047-026-01581-8","authors":["Koichi Inoue","Daisuke Yoshioka","Yusuke Misumi","Ai Kawamura","Shin Yajima","Takuji Kawamura","Shunsuke Saito","Takashi Yamauchi","Shigeru Miyagawa"],"significance":4,"published":"2026-08-29","source_date":"2026-08-21","image":"https://hartvaat.nl/global/img/7f8062705c8a.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/lvad-ventrikelondersteunende-systemen/"],"congress":"","summary_en":"In a single-center retrospective study of 40 patients in Japan, clinical outcomes of left ventricular assist device (LVAD) implantation for destination therapy (DT) were compared with those for bridge-to-transplant (BTT). Five-year on-device survival was 49.8%, with 90.6% of patients experiencing rehospitalization, primarily due to device-related infections. No significant differences were observed between DT and BTT groups in survival or complication rates. These findings support LVAD implantation as a viable option for patients ineligible for heart transplantation.","created":"2026-08-23T00:57:04Z","updated":"2026-08-23T00:57:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een retrospectieve studie van 40 patiënten in Japan werden de resultaten van LVAD-implantatie voor destination therapy (DT) vergeleken met die van brug naar transplantatie (BTT). De 5-jaarsoverleving op het apparaat bedroeg 49,8%, met een hoge rehospitalisatierate van 90,6% voornamelijk door infecties. Er waren geen significante verschillen in overleving of complicaties tussen de DT- en BTT-groep. De bevindingen suggereren dat DT een haalbare optie is voor patiënten die niet in aanmerking komen voor een harttransplantatie.","abstract_original":"The use of left ventricular assist device (LVAD) implantation for destination therapy (DT) has been recently increased worldwide. In 2021, DT was also approved in Japan. Here, we report a single-institution experience of LVAD implantation for DT. This retrospective observational study was conducted at Osaka University Medical Hospital in Japan. Forty patients who underwent LVAD implantation for DT were included. The primary endpoint was on-device survival, and the secondary endpoint was the incidence of LVAD-related complications at five years. The on-device survival rates were 82.3%, 73.3%, and 49.8% at 1, 3, and 5 years, respectively. Most patients (90.6%) experienced rehospitalization during the follow-up period and the most common cause was LVAD-related infection. One-quarter of the patients (10 cases) required LVAD pump exchange, also most commonly due to LVAD-related infection. Comparative analysis with 213 patients who underwent LVAD implantation for bridge to transplant (BTT) revealed no significant change in the primary and secondary outcomes. Our results demonstrate favorable clinical outcomes for LVAD implantation for DT in this Japanese cohort."}